BCLI Brainstorm Cell Therapeutics Inc. Stock Quote

BCLI [NASD]

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	0.10%	Shs Outstand	33.31M	Perf Week	-5.23%
Market Cap	139.37M	Forward P/E	-	EPS next Y	-0.92	Insider Trans	0.00%	Shs Float	29.22M	Perf Month	-33.94%
Income	-31.80M	PEG	-	EPS next Q	-0.26	Inst Own	23.10%	Short Float	14.45%	Perf Quarter	-24.00%
Sales	-	P/S	-	EPS this Y	-0.40%	Inst Trans	19.70%	Short Ratio	3.66	Perf Half Y	-68.11%
Book/sh	1.06	P/B	3.76	EPS next Y	33.30%	ROA	-105.00%	Target Price	-	Perf Year	-42.26%
Cash/sh	1.20	P/C	3.33	EPS next 5Y	-	ROE	-158.50%	52W Range	3.80 - 17.95	Perf YTD	-11.82%
Dividend	-	P/FCF	-	EPS past 5Y	-18.20%	ROI	-	52W High	-77.77%	Beta	0.14
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	-	Gross Margin	-	52W Low	5.00%	ATR	0.61
Employees	40	Current Ratio	3.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	33.34	Volatility	6.70% 9.04%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-4.90%	Profit Margin	-	Rel Volume	0.46	Prev Close	4.15
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.16M	Price	3.99
Recom	3.00	SMA20	-34.46%	SMA50	-27.65%	SMA200	-59.18%	Volume	544,498	Change	-3.86%

Feb-04-21

Upgrade

Maxim Group

Hold → Buy

$12

Nov-17-20

Downgrade

Maxim Group

Buy → Hold

Dec-19-16

Reiterated

Maxim Group

Buy

$5 → $6

Dec-22-15

Reiterated

Maxim Group

Buy

$14 → $5

Mar-03-21 03:49AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI PR Newswire
03:49AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI CNW Group
Feb-26-21 11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation Business Wire
Feb-24-21 03:51PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI PR Newswire
02:50PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation Business Wire
Feb-23-21 08:00AM	BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference PR Newswire -8.08%
Feb-22-21 03:49PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation ACCESSWIRE -33.62%
09:01AM	FDA Concludes BrainStorm's ALS Cell Therapy Lacks Substantial Data For Submission; Shares Drop Benzinga
08:05AM	BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program PR Newswire
Feb-09-21 09:00AM	BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan PR Newswire
Feb-06-21 01:30AM	We Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth Carefully Simply Wall St.
Feb-05-21 07:45AM	BCLI: Waiting for Guidance from FDA on Potential Path Forward for NurOwn® in ALS Zacks Small Cap Research -10.53%
Feb-04-21 06:31PM	Why BrainStorm Cell Therapeutics Blasted 27.7% Higher Today Motley Fool +27.71%
07:00AM	BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate Update PR Newswire
Jan-28-21 08:30AM	BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update PR Newswire +6.14%
Jan-25-21 06:10AM	BCLI: Preclinical Data Shows NurOwn®-Derived Exosomes Effective in ARDS Model Zacks Small Cap Research +9.25%
Jan-20-21 09:08AM	BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS PR Newswire
Dec-28-20 07:00AM	BrainStorm Issues 2020 Letter to Shareholders PR Newswire
Dec-18-20 07:00AM	BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study PR Newswire
Dec-14-20 07:00AM	BrainStorm Announces NurOwn® Expanded Access Program PR Newswire +11.13%
Dec-08-20 12:23AM	Need To Know: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Insiders Have Been Buying Shares Simply Wall St. -6.52%
Nov-26-20 11:36PM	Hedge Funds Arent Crazy About Brainstorm Cell Therapeutics Inc. (BCLI) Anymore Insider Monkey
Nov-23-20 07:00AM	BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND PR Newswire +10.83%
Nov-19-20 07:11AM	BCLI: Phase 3 ALS Trial Does Not Meet Primary Endpoint Zacks Small Cap Research +6.77%
Nov-17-20 12:31PM	Why BrainStorm Cell Therapeutics Stock Imploded Today Motley Fool -66.33%
07:30AM	BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study PR Newswire
Oct-26-20 06:00AM	Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility PR Newswire -5.02%
Oct-23-20 05:30AM	BCLI: Manufacturing Agreement with Catalent; Recent Sell-off Unwarranted Zacks Small Cap Research +5.55%
Oct-22-20 09:00AM	Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn® GlobeNewswire +7.10%
Oct-19-20 07:57AM	BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Outcomes at the Virtual New York Stem Cell Foundation Conference PR Newswire -10.75%
Oct-16-20 06:00AM	BCLI: Phase 3 ALS Data Due Soon Zacks Small Cap Research -9.35%
Oct-15-20 07:00AM	BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update PR Newswire -8.39%
06:00AM	Brainstorm Cell Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-12-20 06:00AM	BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa PR Newswire
Oct-09-20 06:51AM	How Much Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Do Insiders Own? Simply Wall St.
Oct-02-20 01:00AM	BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Corporate Update PR Newswire
Sep-30-20 05:00AM	BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting PR Newswire
Sep-29-20 06:00AM	BrainStorm Appoints William K. White as Senior Vice President, Head of Market Access & Pricing PR Newswire
Sep-16-20 07:30AM	Brainstorm Announces Grant of a New Japanese Patent for NurOwn® PR Newswire
Sep-03-20 09:00AM	BrainStorm to Present at Scientific Conferences in September GlobeNewswire
Sep-02-20 08:30AM	BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs GlobeNewswire +7.66%
Aug-25-20 07:39AM	BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS) PR Newswire
Aug-19-20 08:13AM	BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn® Mechanism in ALS, Progressive MS and Alzheimer's Disease PR Newswire
Aug-10-20 09:03AM	We're Keeping An Eye On Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Rate Simply Wall St.
07:30AM	BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference PR Newswire
Aug-07-20 05:50AM	BCLI: Phase 3 ALS Data Expected by the End of November 2020 Zacks Small Cap Research +5.27%
Aug-05-20 07:00AM	BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update PR Newswire
Jul-27-20 07:58AM	BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update PR Newswire
Jul-23-20 04:36PM	5 Stock Gainers for Thursday: Smith & Wesson, Calix, Sunopta TheStreet.com
07:00AM	BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS GlobeNewswire
Jul-09-20 09:10AM	BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimers Disease; Raising Valuation to $25/Share Zacks Small Cap Research
Jul-08-20 05:31AM	BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program PR Newswire
Jul-02-20 06:49AM	BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS PR Newswire +9.03%
Jul-01-20 08:50AM	BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar PR Newswire
Jun-25-20 08:26AM	The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy Benzinga +13.13%
Jun-24-20 09:06AM	BrainStorm to study stem cell treatment in Alzheimer's patients Reuters
07:00AM	BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease PR Newswire
Jun-23-20 05:45AM	BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index PR Newswire
Jun-15-20 09:00AM	BrainStorm Granted SME Status by the European Medicines Agency GlobeNewswire +17.36%
Jun-11-20 07:28AM	BrainStorm to Present at the Raymond James Human Health Innovations Conference PR Newswire -6.54%
Jun-10-20 05:40AM	BCLI: ALS Association and I AM ALS Awards $500,000 Grant; Potential Inclusion in Russell 3000 Index Zacks Small Cap Research
Jun-09-20 06:00AM	The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study PR Newswire +8.75%
Jun-04-20 07:09PM	Hedge Funds Warming Up To Brainstorm Cell Therapeutics Inc. (BCLI) Insider Monkey
Jun-03-20 06:00AM	BrainStorm to Participate in BIO Digital 2020 PR Newswire
Jun-02-20 06:00AM	BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020 PR Newswire
May-27-20 07:25AM	BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research PR Newswire
May-18-20 06:06AM	Does The Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Share Price Tend To Follow The Market? Simply Wall St. +10.23%
May-08-20 05:35AM	BCLI: The Countdown to Phase 3 ALS Data Begins Zacks Small Cap Research
May-07-20 06:30AM	BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update GlobeNewswire -12.31%
01:00AM	BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union GlobeNewswire
May-04-20 03:30AM	BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology GlobeNewswire
Apr-29-20 06:00AM	BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update GlobeNewswire
Apr-08-20 06:40AM	BCLI: $1.5M Grant from Israel Innovation Authority Zacks Small Cap Research
Apr-03-20 06:59AM	BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority GlobeNewswire
Apr-01-20 09:00AM	David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer GlobeNewswire
Mar-31-20 04:00AM	BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors GlobeNewswire
Mar-16-20 03:00AM	BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19 GlobeNewswire -18.92%
Mar-06-20 09:25AM	BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share GlobeNewswire +12.20%
Feb-27-20 01:00AM	Fifth and Final Site Announced for BrainStorms Progressive Multiple Sclerosis Phase 2 Clinical Trial GlobeNewswire -7.52%
Feb-20-20 05:10AM	BCLI: Phase 3 ALS Results in 4Q20 Zacks Small Cap Research
Feb-18-20 07:00AM	BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 GlobeNewswire +22.67%
06:00AM	Brainstorm Cell Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-17-20 01:00AM	BrainStorms Chief Operating Officer to Present at Noble Capital Markets Sixteenth Annual Investor Conference GlobeNewswire
Feb-11-20 06:00AM	BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS GlobeNewswire +14.74%
Feb-10-20 01:00AM	BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update GlobeNewswire
Feb-04-20 04:45AM	BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference GlobeNewswire
Jan-29-20 04:00AM	BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn® GlobeNewswire
Jan-21-20 09:53AM	BrainStorm Cell Therapeutics COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit GlobeNewswire
Jan-17-20 06:00AM	How Many Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Jan-07-20 01:00AM	BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week GlobeNewswire
Jan-03-20 10:21AM	Weekly CFO Buys Highlight GuruFocus.com
Dec-19-19 05:00AM	NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue GlobeNewswire
Dec-18-19 05:00AM	BrainStorm Issues 2019 Letter to Shareholders GlobeNewswire
Dec-11-19 05:00AM	BrainStorm Selected as Buzz of BIO 2020 Winner GlobeNewswire
Nov-26-19 08:05AM	BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND GlobeNewswire
Nov-25-19 06:00AM	BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site GlobeNewswire
Nov-21-19 06:15AM	BCLI: Phase 3 ALS Trial Fully Enrolled; Phase 2 Results Published in Neurology Zacks Small Cap Research
Nov-20-19 07:00AM	BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology GlobeNewswire
Nov-18-19 06:32AM	Does Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Have A High Beta? Simply Wall St.
Nov-14-19 08:07AM	The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Benzinga

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Setboun David	EVP and COO	Jul 16	Buy	12.95	5,000	64,740	55,000	Jul 16 05:10 PM
ACC International Holdings Ltd	Member of 10% owner group	Jul 16	Sale	13.47	7,823	105,351	67,053	Jul 16 05:05 PM
Abbhi Sankesh	Director	Jul 15	Buy	12.99	46,779	607,659	2,164,530	Jul 16 05:15 PM
ACC International Holdings Ltd	Member of 10% owner group	Jul 15	Sale	13.12	18,430	241,715	74,876	Jul 16 05:05 PM
ACC International Holdings Ltd	Member of 10% owner group	Jul 13	Sale	13.52	40,000	540,952	93,306	Jul 16 05:05 PM
ACC International Holdings Ltd	Member of 10% owner group	Jul 10	Sale	13.35	2,000	26,700	133,306	Jul 16 05:05 PM
ACC International Holdings Ltd	Member of 10% owner group	Jul 09	Sale	13.13	3,500	45,939	135,306	Jul 16 05:05 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience